|
Hyperprolactinemia
|
0.010 |
Biomarker
|
disease |
BEFREE |
Genetic variants in cytochrome P450 (CYP) (CYP2D6), dopamine receptor (DRD2, DRD3) and serotonin receptor (HTR2A, HTR2C) genes were previously associated with antipsychotic-induced hyperprolactinaemia.
|
31520576 |
2020 |
|
Neuralgia
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Involvement of 5-HT2A, 5-HT2B and 5-HT2C receptors in mediating the ventrolateral orbital cortex-induced antiallodynia in a rat model of neuropathic pain.
|
31789691 |
2020 |
|
Tumor Cell Invasion
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
In vitro and in vivo findings with SSRI or pharmacological blockage of the 5-HT(2A)R reveal disruptions of 5-HT signaling within placenta can affect cell proliferation, division, and invasion.
|
31711155 |
2020 |
|
Depersonalization
|
0.010 |
Biomarker
|
disease |
BEFREE |
Its pharmacodynamic mechanisms of action are primarily attributed to the interaction with the serotonergic 5-HT2A-C receptors, and therefore clinical effects are similar to those elicited by other psychoactive substances, such as lysergic acid diethylamide (LSD) and psilocybin, which include euphoria, hallucinations, depersonalization and psychoses.
|
30318013 |
2019 |
|
Neoplasms
|
0.010 |
AlteredExpression
|
group |
BEFREE |
Both neuropeptides were found to increase expression of the specific serotonin (5HT) receptor htr2a, the activation of which has previously been associated with cellular proliferation, suggesting that production of these factors by osteosarcoma cells may act to sensitize tumors to circulating 5HT of local and/or enteric origin.
|
30777054 |
2019 |
|
Osteosarcoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Both neuropeptides were found to increase expression of the specific serotonin (5HT) receptor htr2a, the activation of which has previously been associated with cellular proliferation, suggesting that production of these factors by osteosarcoma cells may act to sensitize tumors to circulating 5HT of local and/or enteric origin.
|
30777054 |
2019 |
|
Seizures
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
25I-NBOH is a new potent serotonin 5-HT2A receptor agonist recently identified in blotter paper seizures.
|
30839986 |
2019 |
|
Stress, Psychological
|
0.010 |
Biomarker
|
disease |
BEFREE |
This study, therefore, suggests that 5-HT2A receptors play a significant role in mediating hyperthermia, but not tachycardia, during intruder-elicited psychological stress.
|
31432430 |
2019 |
|
Arm Pain
|
0.010 |
GeneticVariation
|
phenotype |
BEFREE |
Compared with the no arm pain class, 3 single nucleotide polymorphisms and 1 haplotype, in 4 genes, were associated with membership in the mild arm pain class: COMT rs4633, HTR2A haplotype B02 (composed of rs1923886 and rs7330636), HTR3A rs1985242, and TH rs2070762.
|
30904518 |
2019 |
|
Osteosarcoma of bone
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Both neuropeptides were found to increase expression of the specific serotonin (5HT) receptor htr2a, the activation of which has previously been associated with cellular proliferation, suggesting that production of these factors by osteosarcoma cells may act to sensitize tumors to circulating 5HT of local and/or enteric origin.
|
30777054 |
2019 |
|
Childhood Osteosarcoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Both neuropeptides were found to increase expression of the specific serotonin (5HT) receptor htr2a, the activation of which has previously been associated with cellular proliferation, suggesting that production of these factors by osteosarcoma cells may act to sensitize tumors to circulating 5HT of local and/or enteric origin.
|
30777054 |
2019 |
|
Cognitive changes
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
The 2A subtype of serotonin receptors (5-HT2A receptor) is the major excitatory serotonin receptor in the brain and has been linked to the effects of drugs that produce profound sensory and cognitive changes.
|
30632995 |
2019 |
|
Alzheimer disease, familial, type 3
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Homozygous short (SS) genotype-HTTLPR, GG genotype of HTR2A-rs6311 and CC genotype of HTR2A-rs6313 were associated with AD treatment-induced insomnia, while val/met genotype of BDNF-rs6265 and the TT genotype of GSK-3beta-rs5443 reduced it.
|
31111219 |
2019 |
|
Liver diseases
|
0.010 |
AlteredExpression
|
group |
BEFREE |
Serotonin (5-HT) through its HSCs-expressed receptors, especially 5-HT2A and 7, shows crucial events in fibrogenesis of chronic liver diseases.
|
29660654 |
2018 |
|
Nausea and vomiting
|
0.010 |
GeneticVariation
|
phenotype |
BEFREE |
The present study suggests the association of the HTR2A gene -1438A/G polymorphism with nausea/vomiting as a side effect related to CIT treatment.
|
30221791 |
2018 |
|
Addictive Behavior
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
The serotonin (5-HT) 5-HT2A receptor (5-HT2AR) and 5-HT2C receptor (5-HT2CR) in the central nervous system are implicated in a range of normal behaviors (e.g., appetite, sleep) and physiological functions (e.g., endocrine secretion) while dysfunctional 5-HT2AR and/or 5-HT2CR are implicated in neuropsychiatric disorders (e.g., addiction, obesity, schizophrenia).
|
30157263 |
2018 |
|
Non-alcoholic Fatty Liver Disease
|
0.010 |
Biomarker
|
disease |
BEFREE |
Thus, the gut TPH1-liver HTR2A axis shows promise as a drug target to ameliorate NAFLD with minimal systemic metabolic effects.
|
30446669 |
2018 |
|
Asthenozoospermia
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Gene polymorphisms of HTR2A, MAOA and SLC18A1, related to neurotransmission, are individually associated with asthenozoospermia through variation in sperm count and motility, without detectable allelic or genotype interaction.
|
29602729 |
2018 |
|
Sleep Paralysis
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
This account implicates gene HTR2A on chromosome 13q as the underlying cause of sleep paralysis hallucinations and could be explored using positron emission tomography.
|
30288594 |
2018 |
|
positive and negative symptoms
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Finally, our exploratory analysis suggested that CHRNA7 and HTR2A genes may modulate both positive and negative symptoms responses, while PLA2G4A and SIGMAR1 may modulate respectively positive and negative symptoms responses.
|
29164477 |
2018 |
|
Abnormality of the cranial nerves
|
0.010 |
Biomarker
|
disease |
BEFREE |
The antagonist activities of lurasidone on serotonin 5‑HT7, serotonin 5‑HT2A, serotonin 5‑HT1A and serotonin 5‑HT6 were analyzed, and the preclinical therapeutic effects of lurasidone were examined in a rat model of cranial nerve involvement.
|
29436643 |
2018 |
|
Diffuse Intrinsic Pontine Glioma
|
0.010 |
Biomarker
|
disease |
BEFREE |
GRM1 and HTR2A might function in DIPG through the neuroactive ligand-receptor interaction pathway and the calcium signaling pathway.
|
30124166 |
2018 |
|
Malignant Carcinoid Syndrome
|
0.010 |
Biomarker
|
disease |
BEFREE |
Serotonin syndrome is believed to be due to excessive stimulation of 5-HT2A and 5-HT1A receptors, resulting in the clinical triad of altered mentation, autonomic instability and neuromuscular abnormalities.
|
28594246 |
2017 |
|
nervous system disorder
|
0.010 |
GeneticVariation
|
group |
BEFREE |
5-HT2A Agonists: A Novel Therapy for Functional Neurological Disorders?
|
28177082 |
2017 |
|
Pulmonary Fibrosis
|
0.010 |
Biomarker
|
disease |
BEFREE |
Considering the protective importance of 5-HT receptor antagonists against development of pulmonary fibrosis, we evaluated whether 5-HT7 receptor antagonist (SB-269970) modulates lung inflammatory and fibrogenic processes in comparison with 5-HT2A/B receptor antagonist (terguride), in bleomycin (BLM)-induced idiopathic pulmonary fibrosis (IPF) model.
|
28821451 |
2017 |